Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia

7 de noviembre de 2013 actualizado por: GlaxoSmithKline

A Phase IIa, Randomized, Single-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 28-day Repeat Oral Doses of GSK1278863A in Anemic Pre-dialysis and Hemodialysis-dependent Patients

The purpose of this study is to characterize the safety and efficacy of repeat doses of compound 1278863A in subjects with anemia.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Compound 1278863A is a novel small molecule agent, which stimulates erythropoiesis through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs). This compound is being developed for the treatment of anemia. This study, PHI112844, will be the first administration of compound 1278863A to investigate the pharmacodynamics/efficacy, safety, tolerability, and pharmacokinetics of repeat oral doses in anemic pre-dialysis patients with moderate or severe renal impairment and in hemodialysis-dependent patients.

Tipo de estudio

Intervencionista

Inscripción (Actual)

107

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • GSK Investigational Site
      • Gosford, New South Wales, Australia, 2250
        • GSK Investigational Site
      • St. Leonards, New South Wales, Australia, 2065
        • GSK Investigational Site
    • Queensland
      • Herston, Queensland, Australia, 4029
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • GSK Investigational Site
      • Reservoir, Victoria, Australia, 3073
        • GSK Investigational Site
  • Federación Rusa
      • Ekaterinburg, Federación Rusa, 620102
        • GSK Investigational Site
      • Moscow, Federación Rusa, 125101
        • GSK Investigational Site
      • Moscow, Federación Rusa, 119620
        • GSK Investigational Site
      • Moscow, Federación Rusa, 109240
        • GSK Investigational Site
      • Moscow, Federación Rusa, 115093
        • GSK Investigational Site
      • Moscow, Federación Rusa, 119021
        • GSK Investigational Site
      • Moscow, Federación Rusa, 109472
        • GSK Investigational Site
      • Moscow, Federación Rusa, 123183
        • GSK Investigational Site
      • Nizhny Novgorod, Federación Rusa, 603032
        • GSK Investigational Site
      • Perm, Federación Rusa, 614097
        • GSK Investigational Site
      • Saratov, Federación Rusa, 410053
        • GSK Investigational Site
      • Smolensk, Federación Rusa, 214006
        • GSK Investigational Site
      • St-Petersburg, Federación Rusa, 197110
        • GSK Investigational Site
      • St. Petersburg, Federación Rusa, 196247
        • GSK Investigational Site
      • St. Petersburg, Federación Rusa, 197022
        • GSK Investigational Site
      • St. Petersburg, Federación Rusa, 191104
        • GSK Investigational Site
      • St. Petersburg, Federación Rusa, 191015
        • GSK Investigational Site
      • St. Petersburg, Federación Rusa, 191186
        • GSK Investigational Site
      • St. Petersburg, Federación Rusa, 195067
        • GSK Investigational Site
      • Volzhsky, Federación Rusa, 404120
        • GSK Investigational Site
      • Yaroslavl, Federación Rusa, 150062
        • GSK Investigational Site
  • India
      • Bangalore, India, 560017
        • GSK Investigational Site
      • Bangalore, India, 560004
        • GSK Investigational Site
      • Hyderabad, India, 500012
        • GSK Investigational Site
      • Hyderabad, India, 5000068
        • GSK Investigational Site
      • Kalapet Pondicherry, India, 605014
        • GSK Investigational Site
      • Mumbai, India, 400008
        • GSK Investigational Site
      • New Delhi, India
        • GSK Investigational Site
      • Vishakha Patnam, India, 530002
        • GSK Investigational Site
  • Nueva Zelanda
      • Auckland, Nueva Zelanda, 1150
        • GSK Investigational Site
      • Christchurch, Nueva Zelanda, 8140
        • GSK Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent.

  2. A male or female is eligible to enroll and participate in this study if he/she:

    1. (Part 1) has Moderate to Severe Renal Impairment (equivalent to NKF KDOQI Stage 3 or 4, not receiving dialysis) as determined by estimated Glomerular Filtration Rate (eGFR) calculated by the abbreviated MDRD equation, and not expected to go on dialysis until ≥ 8 weeks after first administration of investigational product. Stage 5, non-dialysis patients with eGFR of 10 15 mL/min per 1.73 m2 will also be eligible for Part 1 on a case-by-case basis.
    2. (Part 2) has Severe Renal Impairment and has been on stable hemodialysis treatment for 1 month prior to Screening (subjects with planned transition to hemodialysis) or 3 months prior to Screening (subjects emergently placed on hemodialysis). These subjects are equivalent to NKF KDOQI Stage 5.
    3. otherwise healthy or considered clinically stable with respect to underlying renal impairment and with respect to underlying/chronic disease as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
    4. has clinical laboratory test results that are considered clinically stable in the opinion of the principal investigator, especially if the clinical abnormality or laboratory parameter is deemed associated with the patient's underlying renal impairment.

  3. Meets the following erythropoiesis stimulating agent (ESA) criteria:

    1. The patient is ESA naïve OR
    2. If the patient has a scheduled ESA interval which is ≤ 7 days, ESA treatment must be discontinued for at least 7 days OR
    3. If the patient has a scheduled ESA interval which is > 7 days, ESA treatment must be discontinued for at least that scheduled interval length (eg discontinued ≥ 14 days for a scheduled 14 day ESA interval) AND The patient will not resume ESA treatment until completion of the Follow-up Visit (Day 57).

  4. Has a hemoglobin value:

    1. For ESA naïve patients: ≤11.0 g/dL
    2. For patients receiving ongoing ESA treatment: ≤11.5 g/dL at Screening with a re check value of ≤11.0 g/dL after appropriate ESA discontinuation according to Inclusion 3 and prior to commencing study drug dosing.

  5. 5. Has serum ferritin at Screening:

    1. ≥40 μg/L with the absence of microcytic or hypochromic RBCs (regardless of transferrin saturation %) OR
    2. 25-39 μg/L with transferrin saturation % ≥20% (fraction saturation ≥0.20) and the absence of microcytic or hypochromic RBCs
  6. Has Vitamin B12 and folate above the lower limit of normal at Screening

  7. A female patient is eligible to participate if she is:

    1. of childbearing potential, and must agree to use one of the contraception methods in Section 8.1.1. This criterion must be followed from the time of Screening until completion of the Follow-up Visit (Day 57) OR
    2. of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  8. Male patients must agree to use one of the contraception methods listed in Section 8.1.2. This criterion must be followed from the time of the first dose of study drug until completion of the Follow-up Visit (Day 57).
  9. Body weight ≥ 45 kg
  10. QTcB or QTcF < 450 msec; or QTc < 480 msec in patients with bundle branch block. These should be based on an average of triplicate values obtained at Screening.
  11. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  1. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months prior to Screening and one of the following:

    • evidence of autoimmune anemia
    • prior anti-viral therapy
    • evidence of liver damage
  2. A positive test for HIV antibody.
  3. A pre-study drug screen that is positive due to drug use not associated with a current medication prescription. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  4. A value at Screening is greater than 1.5 times the upper limit of reference range for AST, ALT, or direct bilirubin.
  5. Hemolysis/hemolytic anemia or active bleeding/blood loss
  6. Androgen therapy within 8 weeks prior to first dose of study drug (Day 1).
  7. Red blood cell transfusion within 90 days prior to first dose of study drug (Day 1).

  8. 8. Iron replacement therapy:

    1. Intravenous iron replacement therapy within 30 days prior to the first dose of study drug on Day 1 until completion of the Follow-up Visit (Day 57).
    2. Oral iron replacement therapy started or discontinued within 30 days prior to Screening. (Patients currently receiving oral iron replacement therapy which was initiated at least 30 days prior to Screening, will be allowed to continue their oral iron replacement therapy during the study and should not discontinue the therapy until after completion of all study drug doses and Day 29 assessments.)
  9. History of thrombosis defined as deep vein thrombosis, stroke, pulmonary embolism or other thrombosis related condition within 1 year prior to Screening.
  10. Known active decompensated hyperparathyroidism or history of bone marrow fibrosis.
  11. Systemic hematologic disease, including, but not limited to sickle cell disease, hemosiderosis, hemochromatosis, myelodysplastic syndrome, hematologic malignancy, myeloma
  12. Post-renal transplantation patients with functioning transplant. (Failed transplant subjects back on hemodialysis are eligible).
  13. Acute peptic ulcer disease or history of chronic rectal bleeding.
  14. History of malignancy tumor within 5 years prior to Screening or are receiving medication for cancer. Non-melanoma skin cancer within the past 5 years that has been definitively removed is allowed.
  15. Patients with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Examples of conditions that could interfere with normal gastrointestinal anatomy or motility include gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption, Crohn's disease, ulcerative colitis, or celiac sprue. Examples of conditions that could interfere with hepatic function include Gilberts syndrome.
  16. Active infection or acute inflammatory disease as determined by clinical assessment.
  17. Class III heart failure with evidence of recent progression (worsening dyspnea, hospitalization within 2-3 months for symptoms, etc), or Class IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system.
  18. Uncontrolled hypertension (diastolic BP >100 mmHg or systolic BP >160 mmHg at Screening)
  19. Myocardial infarction or acute coronary syndrome within 1 year prior to Screening.
  20. History of seizure disorder.
  21. Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy that is likely to require treatment (intraocular injections or laser photocoagulation) during the study.
  22. Pregnant females as determined by positive serum or urine hCG test at Screening or prior to the first dose of study drug (Day 1).
  23. Lactating females.
  24. History of drug abuse or dependence within 6 months prior to Screening.
  25. Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol.

  26. Use of prescription drugs within 7 days prior to first dose of study drug (Day 1) until after completion of all study drug doses and Day 29 assessments:

    • which are know to be inhibitors of CYP 2C8 OR
    • which are known to be both CYP 2C8 and OATP1B1 substrates OR
    • which rely mainly on OATP1B1/1B3 for hepatic clearance as described in Section 9 of the protocol.
  27. Use of prescription drugs within 14 days prior to first dose of study drug (Day 1) until completion of all study drug doses and Day 29 assessments, which are known to be inducers of CYP 2C8, as described in Section 9 of the protocol.
  28. Use of non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study drug (Day 1) through the Follow-up Visit (Day 57), unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise patient safety and GSK Medical Monitor concurs.
  29. History of sensitivity to any of the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  30. History of sensitivity to heparin or heparin-induced thrombocytopenia. (if the clinical site uses heparin to maintain intravenous cannula patency)
  31. The patient has participated in a clinical trial and has received an experimental investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  32. Exposure to more than four experimental investigational products within 12 months prior to the first dose of study drug (Day 1).
  33. Patient is mentally or legally incapacitated.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Grupo 2
Placebo
Droga: Placebo
placebo coincidente
Experimental: Group 1
Active Drug
Droga: 1278863A
25mg, 50mg, 100mg

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Informe de eventos adversos
Periodo de tiempo: a lo largo del estudio
a lo largo del estudio
Rate of response for increase from baseline of hemoglobin levels
Periodo de tiempo: Pre-dose, Day 1, Day 15, Day 22, Follow-up
Pre-dose, Day 1, Day 15, Day 22, Follow-up
Safety Labs (Chemistry)
Periodo de tiempo: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Safety Labs (Hematology)
Periodo de tiempo: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Safety Labs (Urinalysis)
Periodo de tiempo: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Vital Signs (blood pressure and heart rate)
Periodo de tiempo: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
ECG
Periodo de tiempo: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
AUC (0-∞), Cmax, tmax, t½
Periodo de tiempo: Day 1, 15, 22
Day 1, 15, 22
Actual values and change from baseline for erythropoietin, absolute and percent reticulocytes, hematocrit, and total RBCs
Periodo de tiempo: Day 1, 15, 22, Folllow-up
Day 1, 15, 22, Folllow-up
Actual values and change from baseline for VEGF, hepcidin, TIBC
Periodo de tiempo: Day 1, 15, 22, Follow-up
Day 1, 15, 22, Follow-up
Actual values and change from baseline for transferrin saturation, serum iron, serum ferritin
Periodo de tiempo: Screening, Day 1, 15, 29, 57
Screening, Day 1, 15, 29, 57
Actual value and change from baseline for fetal hemoglobin
Periodo de tiempo: Day 1, 29, 57
Day 1, 29, 57

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

GlaxoSmithKline

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de marzo de 2010

Finalización primaria (Actual)

1 de febrero de 2011

Finalización del estudio (Actual)

1 de febrero de 2011

Fechas de registro del estudio

Enviado por primera vez

11 de enero de 2010

Primero enviado que cumplió con los criterios de control de calidad

11 de enero de 2010

Publicado por primera vez (Estimar)

12 de enero de 2010

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

11 de noviembre de 2013

Última actualización enviada que cumplió con los criterios de control de calidad

7 de noviembre de 2013

Última verificación

1 de julio de 2013

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 112844
  • PHI112844 (Otro identificador: Octagon Research)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Enfermedad del riñon

Buscar ensayos similares

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

CROs by country

CROs in Jamaica

Condiciones

Enfermedades Raras

Intervenciones de drogas

Suplementos dietéticos

Patrocinador / Colaboradores

Localizaciones

Suscribir